Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid

BMC Res Notes. 2022 Jan 10;15(1):12. doi: 10.1186/s13104-021-05900-5.

Abstract

Objectives: This study aimed to investigate the gene expression of angiogenic marker in surgically treated jawbones and femur on a rat model administrated with zoledronic acid.

Results: No soft tissue fenestration or bone exposure was found in femur. Delayed soft tissue healing was found in both ZA group (3 in mandible, 4 in maxilla) and control group (1 in mandible, 2 in maxilla), while exposed bone was found only in the ZA group (1 in maxilla, 2 in mandible). RT-PCR analysis demonstrated no significant difference in gene expression of angiogenetic markers between ZA-treated and control groups in femur and mandible. In the maxilla, the expression of VEGFA and VEGFR-2 in medium-term ZA group was significantly down-regulated compared with that in the control. The ZA treatment does not change significantly the expression of the angiogenic factors in femur and mandible, but significantly downregulates the expression in maxilla in this rat model. The angiogenesis inhibition may contribute to the development of MRONJ but does not play a key role.

Keywords: Angiogenic markers; Animal model; Gene expression; Medication-related osteonecrosis of the jaw; Zoledronic acid.

MeSH terms

  • Animals
  • Bone Density Conservation Agents*
  • Diphosphonates*
  • Femur
  • Rats
  • Tooth Extraction
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Zoledronic Acid